Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

3.

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G.

J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.

4.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.

5.

Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.

Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, Matsuda E, Maekawa R, Goto S.

Anticancer Res. 2013 Jul;33(7):2971-6.

PMID:
23780988
7.

Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.

Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, Nakamura M, Sugiyama H, Yonemitsu Y, Okamoto M, Hongo K.

J Neurosurg. 2015 Oct;123(4):989-97. doi: 10.3171/2015.1.JNS141554. Epub 2015 Aug 7.

PMID:
26252465
8.
9.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
10.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.

J Transl Med. 2011 Oct 20;9:178. doi: 10.1186/1479-5876-9-178.

11.

Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.

Oncology. 2005;68(2-3):163-70. Epub 2005 Jul 4.

PMID:
16006753
12.

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.

Cancer Res. 2004 Jul 15;64(14):4973-9.

13.

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.

Guo Y, Lei K, Tang L.

Front Immunol. 2018 Jul 2;9:1499. doi: 10.3389/fimmu.2018.01499. eCollection 2018. Review.

14.

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M.

Hum Cell. 2003 Dec;16(4):175-82. Review.

PMID:
15147037
15.
16.
17.

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.

de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Riccobon A, Parisi E, Romeo A, Turci L, Guidoboni M.

J Transl Med. 2014 Jul 22;12:209. doi: 10.1186/1479-5876-12-209.

18.

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.

Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR.

Exp Hematol. 2006 Oct;34(10):1403-12.

PMID:
16982333
19.

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G.

J Transl Med. 2011 Nov 14;9:198. doi: 10.1186/1479-5876-9-198.

20.

The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.

Salem ML.

Methods Mol Biol. 2014;1139:479-503. doi: 10.1007/978-1-4939-0345-0_37. Review.

PMID:
24619701

Supplemental Content

Support Center